We can’t show the full text here under this license. Use the link below to read it at the source.
Adjunctive bright light therapy to enhance continuous positive airway pressure adherence in patients with comorbid major depressive disorder and obstructive sleep apnoea syndrome: study protocol for a randomised sham-controlled trial
Bright light therapy to improve CPAP use in patients with depression and sleep apnea: study plan for a controlled trial
AI simplified
Abstract
A total of 130 patients with both major depressive disorder and obstructive sleep apnoea syndrome will participate in a trial assessing the impact of on adherence.
- Approximately 50% of patients with obstructive sleep apnoea syndrome also experience major depressive disorder, leading to more severe symptoms and poorer outcomes.
- Continuous positive airway pressure therapy is effective for treating obstructive sleep apnoea but often suffers from poor adherence in the initial treatment weeks.
- Bright light therapy has been shown to improve mood, cognitive function, and sleep in patients with major depressive disorder.
- The trial will compare adherence to CPAP therapy between patients receiving active bright light therapy and those receiving a sham treatment over 14 days.
- Primary outcomes will measure CPAP adherence, while secondary outcomes will assess changes in depressive and anxiety symptoms, as well as sleep-related parameters.
AI simplified
Key numbers
130
Participants
Total number of patients enrolled in the trial.
14
Sessions of Therapy
Number of sessions for both active and sham .
0.5
Hours of Use
Expected difference in mean adherence between active and sham groups.